Source:http://linkedlifedata.com/resource/pubmed/id/20067770
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
2010-3-9
|
pubmed:abstractText |
Inflammation-induced microsomal prostaglandin E synthase-1 (mPGES-1) is the terminal enzyme that synthesizes prostaglandin E(2) (PGE(2)) downstream of cyclooxygenase-2 (COX-2). The efficacy of nonsteroidal anti-inflammatory drugs and COX-2 inhibitors in the treatment of the signs and symptoms of osteoarthritis, rheumatoid arthritis and inflammatory pain, largely attributed to the inhibition of PGE(2) synthesis, provides a rationale for exploring mPGES-1 inhibition as a potential novel therapy for these diseases. Toward this aim, we identified PF-9184 as a novel mPGES-1 inhibitor. PF-9184 potently inhibited recombinant human (rh) mPGES-1 (IC(50)=16.5+/-3.8nM), and had no effect against rhCOX-1 and rhCOX-2 (>6500-fold selectivity). In inflammation and clinically relevant biological systems, mPGES-1 expression, like COX-2 expression was induced in cell context- and time-dependent manner, consistent with the kinetics of PGE(2) synthesis. In rationally designed cell systems ideal for determining direct effects of the inhibitors on mPGES-1 function, but not its expression, PF-9184 inhibited PGE(2) synthesis (IC(50) in the range of 0.5-5 microM in serum-free cell and human whole blood cultures, respectively) while sparing the synthesis of 6-keto-PGF(1alpha) (PGF(1alpha)) and PGF(2alpha). In contrast, as expected, the selective COX-2 inhibitor, SC-236, inhibited PGE(2), PGF(1alpha) and PGF(2alpha) synthesis. This profile of mPGES-1 inhibition, distinct from COX-2 inhibition in cells, validates mPGES-1 as an attractive target for therapeutic intervention.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Carrageenan,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclic S-Oxides,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2 Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-1beta,
http://linkedlifedata.com/resource/pubmed/chemical/Intramolecular Oxidoreductases,
http://linkedlifedata.com/resource/pubmed/chemical/Thiazines,
http://linkedlifedata.com/resource/pubmed/chemical/prostaglandin-E synthase
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1873-2968
|
pubmed:author |
pubmed-author:CarterJeffJ,
pubmed-author:GierseJames KJK,
pubmed-author:MasferrerJaime LJL,
pubmed-author:MathialaganSumathyS,
pubmed-author:MbalavieleGabrielG,
pubmed-author:MnichStephen JSJ,
pubmed-author:MooreWilliam MWM,
pubmed-author:NemirovskiyOlga VOV,
pubmed-author:PauleyAdele MAM,
pubmed-author:ShafferAlexander FAF,
pubmed-author:VazquezMichael LML,
pubmed-author:WangJane LJL,
pubmed-author:ZweifelBen SBS
|
pubmed:copyrightInfo |
2010 Elsevier Inc. All rights reserved.
|
pubmed:issnType |
Electronic
|
pubmed:day |
15
|
pubmed:volume |
79
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1445-54
|
pubmed:meshHeading |
pubmed-meshheading:20067770-Animals,
pubmed-meshheading:20067770-Arthritis, Rheumatoid,
pubmed-meshheading:20067770-Carrageenan,
pubmed-meshheading:20067770-Cells, Cultured,
pubmed-meshheading:20067770-Cyclic S-Oxides,
pubmed-meshheading:20067770-Cyclooxygenase 2,
pubmed-meshheading:20067770-Cyclooxygenase 2 Inhibitors,
pubmed-meshheading:20067770-Fibroblasts,
pubmed-meshheading:20067770-Gene Expression,
pubmed-meshheading:20067770-Humans,
pubmed-meshheading:20067770-Immunoblotting,
pubmed-meshheading:20067770-Interleukin-1beta,
pubmed-meshheading:20067770-Intramolecular Oxidoreductases,
pubmed-meshheading:20067770-Microsomes,
pubmed-meshheading:20067770-Rats,
pubmed-meshheading:20067770-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:20067770-Thiazines
|
pubmed:year |
2010
|
pubmed:articleTitle |
Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor.
|
pubmed:affiliation |
Pfizer Inc., Chesterfield, MO 63017, USA. gabriel.mbalaviele@pfizer.com
|
pubmed:publicationType |
Journal Article
|